Esperion Therapeutics (NASDAQ:ESPR) Rating Increased to Buy at StockNews.com

StockNews.com upgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from a hold rating to a buy rating in a research report sent to investors on Tuesday morning.

Other equities research analysts have also issued research reports about the stock. Bank of America lowered shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and dropped their price objective for the stock from $2.90 to $2.50 in a research note on Thursday, June 20th. Needham & Company LLC dropped their price target on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research report on Wednesday, October 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Esperion Therapeutics currently has a consensus rating of “Hold” and an average target price of $8.17.

Esperion Therapeutics Stock Down 3.3 %

ESPR opened at $2.04 on Tuesday. Esperion Therapeutics has a 52 week low of $0.71 and a 52 week high of $3.40. The stock has a market cap of $386.50 million, a PE ratio of -2.06 and a beta of 1.00. The business has a 50 day moving average of $1.83 and a 200-day moving average of $2.16.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Monday, August 12th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.10. The firm had revenue of $73.83 million for the quarter, compared to analysts’ expectations of $51.90 million. Equities analysts anticipate that Esperion Therapeutics will post -0.04 EPS for the current year.

Institutional Investors Weigh In On Esperion Therapeutics

Institutional investors have recently made changes to their positions in the company. Bellevue Group AG lifted its position in Esperion Therapeutics by 136.5% in the 1st quarter. Bellevue Group AG now owns 9,944,064 shares of the biopharmaceutical company’s stock valued at $26,650,000 after acquiring an additional 5,739,800 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Esperion Therapeutics by 71.8% in the first quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock worth $23,655,000 after purchasing an additional 3,688,796 shares during the last quarter. Marshall Wace LLP lifted its holdings in shares of Esperion Therapeutics by 94.2% during the second quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock valued at $9,554,000 after purchasing an additional 2,087,635 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Esperion Therapeutics by 3,278.3% during the second quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company’s stock valued at $1,271,000 after buying an additional 555,382 shares during the last quarter. Finally, Inspire Investing LLC bought a new stake in Esperion Therapeutics in the 2nd quarter worth about $758,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.